デフォルト表紙
市場調査レポート
商品コード
1566971

結膜炎市場:タイプ別、疾患タイプ別、エンドユーザー別:世界の機会分析と産業予測、2024~2033年

Conjunctivitis Market By Type , By Disease Type By End User : Global Opportunity Analysis and Industry Forecast, 2024-2033


出版日
ページ情報
英文 228 Pages
納期
2~3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.30円
結膜炎市場:タイプ別、疾患タイプ別、エンドユーザー別:世界の機会分析と産業予測、2024~2033年
出版日: 2024年07月10日
発行: Allied Market Research
ページ情報: 英文 228 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

結膜炎市場は2023年に48億米ドルと評価され、2024~2033年にかけてCAGR 4.1%で成長し、2033年には72億米ドルに達すると予測されています。

結膜炎は、結膜(白目の部分とまぶたの内側を覆う薄い透明な膜)に炎症を起こす最も一般的な眼感染症です。ウイルスや細菌感染、アレルゲン、刺激物など、さまざまな要因によって引き起こされます。この症状は、充血、かゆみ、腫れ、目からの分泌物などの症状が特徴です。結膜炎はしばしば不快で伝染しやすいが、通常は治療可能であり、重篤な合併症を引き起こすことはまれです。

世界の結膜炎市場の成長は、特に結膜炎が頻繁に発生する地域で結膜炎の有病率が高く、治療や予防対策への需要が高まっていることが背景にあります。Medscape(医療ニュース、臨床試験報道、医薬品最新情報へのアクセスを提供するウェブサイト)が2024年に発表した調査によると、米国では年間600万件のウイルス性結膜炎が新たに発生していると推定されています。公害や花粉などの環境要因によるアレルギー性結膜炎の症例の増加が、関連治療への需要を押し上げています。さらに、特に学校や公共輸送のような混雑した環境では、ウイルス感染や細菌感染が頻繁に発生するため、効果的な治療オプションの必要性が高まっています。さらに、消費者の意識の高まりと処方箋なしでこれらの製品にアクセスできる利便性により、市販のアイケア製品への嗜好が高まっていることも、市場の成長に大きく寄与しています。さらに、高齢者人口の急増も市場の成長を後押ししています。これは、結膜を含む目の組織が自然に変性するという事実に起因しています。このため、高齢者の目は刺激、感染、炎症を起こしやすくなり、結膜炎のような症状を発症する可能性が高くなります。個別化医療の動向は、個々の患者プロファイルや特定の結膜炎の原因に基づいたオーダーメイド治療を促進することで、結膜炎市場にさらに影響を与えています。しかし、多くの人が結膜炎を自己診断し、市販品や家庭薬で自己治療しているため、誤った治療や症状の悪化につながる可能性があります。誤診は不適切な薬の使用にもつながり、これが世界市場の主要阻害要因となっています。さらに、医療サービスや眼科専門医へのアクセスが限られているため、結膜炎のタイムリーな診断と治療が妨げられ、合併症の発生率が高くなるため、市場の成長が抑制されます。逆に、製薬研究の進歩により、結膜炎の新規抗菌薬や抗炎症治療など、より効果的な新規治療の開発が進んでいます。さらに、結膜炎の診断と治療計画の精度とスピードを向上させるために、診断ツールにAIとMLを統合することが、市場成長に新たな道を提供すると予想されます。

世界の結膜炎市場は、タイプ、疾患タイプ、エンドユーザー、地域に区分されます。タイプ別では、市場は診断と治療に二分されます。診断セグメントはさらに、身体試験と臨床試験に区分されます。治療セグメントはさらに、抗生物質、抗ウイルス剤、抗アレルギー剤、人工涙液に分類されます。疾患タイプに基づき、市場はアレルギー性結膜炎、細菌性結膜炎、ウイルス性結膜炎に分けられます。アレルギー性結膜炎はさらに、季節性アレルギー性結膜炎と通年性アレルギー性結膜炎に分類されます。エンドユーザー別では、病院&クリニック、専門眼科クリニック、その他に分類されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されます。

主要調査結果

タイプ別では、治療セグメントが2023年の市場で最大シェアを占めました。

疾患タイプ別では、アレルギー性結膜炎セグメントが2023年の市場を独占しました。

エンドユーザー別では、病院・クリニックが2023年の主要セグメントとして浮上しました。

地域別では、北米が2023年の結膜炎市場の主要株主であり、予測期間を通じてその優位性を維持すると予測されます。

本レポートはカスタマイズが可能です。

  • 規制ガイドライン
  • 顧客の関心に応じた企業プロファイルの追加
  • 国別または地域別の追加分析-市場規模と予測
  • 企業プロファイルの拡大リスト
  • 過去の市場データ
  • 主要参入企業の詳細(所在地、連絡先、サプライヤー/ベンダーネットワークなどを含む、エクセル形式)

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場情勢

  • 市場の定義と範囲
  • 主要調査結果
    • 主要投資機会
    • 主要成功戦略
  • ポーターのファイブフォース分析
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会

第4章 結合炎市場:タイプ別

  • 市場概要
  • 診断
    • 身体試験
    • 臨床試験
  • 治療
    • 抗生物質
    • 抗ウイルス剤
    • 抗アレルギー剤
    • 人工涙液

第5章 結合炎市場:疾患タイプ別

  • 市場概要
  • アレルギー性結膜炎
    • 季節性アレルギー性結膜炎
    • 通年性アレルギー性結膜炎
  • 細菌性結膜炎
  • ウイルス性結膜炎

第6章 結膜炎市場:エンドユーザー別

  • 市場概要
  • 病院とクリニック
  • 専門眼科クリニック
  • その他

第7章 統合失調症市場結合炎市場:地域別

  • 市場概要
  • 北米
    • 主要市場動向と機会
    • 米国の結膜炎市場
    • カナダの結膜炎市場
    • メキシコ結膜炎市場
  • 欧州
    • 主要市場動向と機会
    • ドイツの結膜炎市場
    • フランスの結膜炎市場
    • 英国の結膜炎市場
    • イタリアの結膜炎市場
    • スペインの結膜炎市場
    • その他の欧州結膜炎市場
  • アジア太平洋
    • 主要市場動向と機会
    • 日本の結膜炎市場
    • 中国の結膜炎市場
    • インドの結膜炎市場
    • オーストラリアの結膜炎市場
    • 韓国の結膜炎市場
    • その他のアジア太平洋の結膜炎市場
  • ラテンアメリカ・中東・アフリカ
    • 主要市場動向と機会
    • ブラジルの結膜炎市場
    • サウジアラビアの結膜炎市場
    • 南アフリカの結膜炎市場
    • その他のラテンアメリカ・中東・アフリカの結膜炎市場

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10企業の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • 主要企業のポジショニング(2023年)

第9章 企業プロファイル

  • AFT Pharmaceuticals
  • Alembic Pharmaceuticals Ltd
  • Johnson And Johnson Services Inc
  • Ocular Therapeutics, Inc
  • Cipla, Inc.
  • Jabs Biotech Pvt. Ltd.
  • Spectra Vision Care Pvt. Ltd
  • Teva Pharmaceutical Industries Ltd
  • Grevis Pharmaceutical Private Limited
  • Bausch Health Companies Inc
目次
Product Code: A324393

The conjunctivitis market was valued at $4.8 billion in 2023, and is projected to reach $7.2 billion by 2033, growing at a CAGR of 4.1% from 2024 to 2033.

Conjunctivitis is the most prevalent eye infection that causes the inflammation of the conjunctiva-the thin, transparent membrane that lines the white part of the eye and the inner surface of the eyelids. It can be caused by various factors, including viral or bacterial infections, allergens, or irritants. This condition is characterized by symptoms such as redness, itching, swelling, and discharge from the eye. While often uncomfortable and contagious, conjunctivitis is typically treatable and rarely causes serious complications.

The growth of the global conjunctivitis market is driven by high prevalence of conjunctivitis, particularly in regions with frequent outbreaks, drives demand for treatment and preventive measures. According to a 2024 study published by Medscape-website providing access to medical news, clinical trial coverage, drug updates-an estimated 6 million new cases of viral conjunctivitis occur annually in the U.S. Increase in cases of allergic conjunctivitis due to environmental factors, such as pollution and pollen, boosts the demand for relevant therapies. Moreover, frequent outbreaks of viral or bacterial infections, especially in crowded settings like schools and public transport, foster the need for effective treatment options. Furthermore, increase in preference for over-the-counter eye care products, driven by increased consumer awareness and the convenience of accessing these products without prescription, notably contributes toward the market growth. In addition, surge in geriatric population propels the market growth. This is attributed to the fact that the tissues in the eyes, including the conjunctiva, undergoes natural degeneration. This makes the eyes of aged individuals more prone to irritation, infections, and inflammation, leading to a higher likelihood of developing conditions like conjunctivitis, which augments the demand for specialized treatments. The trend toward personalized medicine is further impacting the conjunctivitis market by promoting tailored treatments based on individual patient profiles and specific conjunctivitis causes. However, many individuals self-diagnose and self-treat conjunctivitis with over-the-counter products or home remedies, which can lead to incorrect treatment and potential worsening of the condition. Misdiagnosis can also result in inappropriate use of medications, which acts as the key deterrent factor of the global market. In addition, limited access to healthcare services and eye care professionals hinders timely diagnosis and treatment of conjunctivitis, leading to higher rates of complications, thus restraining the market growth. On the contrary, advances in pharmaceutical research are leading to the development of new and more effective therapies, including novel antimicrobial agents and anti-inflammatory treatments for conjunctivitis. Furthermore, integration of AI and ML in diagnostic tools to improve the accuracy and speed of conjunctivitis diagnosis and treatment planning is anticipated to offer new avenues for the market growth.

The global conjunctivitis market is segmented into type, disease type, end user, and region. On the basis of the type, the market is bifurcated into diagnosis and treatment. The diagnosis segment is further segmented into physical examination and laboratory tests. The treatment segment is further classified into antibiotics, antiviral, anti-allergic, and artificial tears. Depending on disease type, the market is divided into allergic conjunctivitis, bacterial conjunctivitis, and viral conjunctivitis. The allergic conjunctivitis segment is further categorized into seasonal allergic conjunctivitis and perennial allergic conjunctivitis. As per end user, the market is classified into hospitals & clinics, specialty eye clinics, and others. By region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the treatment segment accounted for the largest share of the market in 2023.

On the basis of disease type, the allergic conjunctivitis segment dominated the market in 2023.

Depending on end user, hospital & clinics emerged as the leading segment in 2023.

Region wise, North America was the major shareholder in the conjunctivitis market in 2023, and is expected to retain its dominance throughout the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global conjunctivitis market include AFT Pharmaceuticals, Alembic Pharmaceuticals Ltd., Johnson & Johnson Services Inc., Ocular Therapeutics, Inc., Cipla, Inc., Jabs Biotech Pvt. Ltd., Spectra Vision Care Pvt. Ltd., Teva Pharmaceutical Industries Ltd., Grevis Pharmaceutical Private Limited, and Bausch Health Companies Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Diagnosis
    • Physical Examination
    • Laboratory Tests
  • Treatment
    • Antibiotics
    • Antiviral
    • Anti-allergic
    • Artificial Tears

By Disease Type

  • Allergic Conjunctivitis
    • Seasonal Allergic Conjunctivitis
    • Perennial Allergic Conjunctivitis
  • Bacterial Conjunctivitis
  • Viral Conjunctivitis

By End User

  • Hospitals and Clinics
  • Specialty Eye Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • AFT Pharmaceuticals
    • Alembic Pharmaceuticals Ltd
    • Johnson & Johnson Services Inc
    • Ocular Therapeutics, Inc
    • Cipla, Inc.
    • Jabs Biotech Pvt. Ltd.
    • Spectra Vision Care Pvt. Ltd
    • Teva Pharmaceutical Industries Ltd
    • Grevis Pharmaceutical Private Limited
    • Bausch Health Companies Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: CONJUNCTIVITIS MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Diagnosis
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
    • 4.2.5. Physical Examination
      • 4.2.5.1. Market Size and Forecast
    • 4.2.6. Laboratory Tests
      • 4.2.6.1. Market Size and Forecast
  • 4.3. Treatment
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
    • 4.3.5. Antibiotics
      • 4.3.5.1. Market Size and Forecast
    • 4.3.6. Antiviral
      • 4.3.6.1. Market Size and Forecast
    • 4.3.7. Anti-allergic
      • 4.3.7.1. Market Size and Forecast
    • 4.3.8. Artificial Tears
      • 4.3.8.1. Market Size and Forecast

CHAPTER 5: CONJUNCTIVITIS MARKET, BY DISEASE TYPE

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Disease Type
  • 5.2. Allergic Conjunctivitis
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
    • 5.2.5. Seasonal Allergic Conjunctivitis
      • 5.2.5.1. Market Size and Forecast
    • 5.2.6. Perennial Allergic Conjunctivitis
      • 5.2.6.1. Market Size and Forecast
  • 5.3. Bacterial Conjunctivitis
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Viral Conjunctivitis
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: CONJUNCTIVITIS MARKET, BY END USER

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By End User
  • 6.2. Hospitals And Clinics
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Specialty Eye Clinics
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Others
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: CONJUNCTIVITIS MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Type
    • 7.2.3. Market Size and Forecast, By Disease Type
    • 7.2.4. Market Size and Forecast, By End User
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Conjunctivitis Market
      • 7.2.6.1. Market Size and Forecast, By Type
      • 7.2.6.2. Market Size and Forecast, By Disease Type
      • 7.2.6.3. Market Size and Forecast, By End User
    • 7.2.7. Canada Conjunctivitis Market
      • 7.2.7.1. Market Size and Forecast, By Type
      • 7.2.7.2. Market Size and Forecast, By Disease Type
      • 7.2.7.3. Market Size and Forecast, By End User
    • 7.2.8. Mexico Conjunctivitis Market
      • 7.2.8.1. Market Size and Forecast, By Type
      • 7.2.8.2. Market Size and Forecast, By Disease Type
      • 7.2.8.3. Market Size and Forecast, By End User
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Type
    • 7.3.3. Market Size and Forecast, By Disease Type
    • 7.3.4. Market Size and Forecast, By End User
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. Germany Conjunctivitis Market
      • 7.3.6.1. Market Size and Forecast, By Type
      • 7.3.6.2. Market Size and Forecast, By Disease Type
      • 7.3.6.3. Market Size and Forecast, By End User
    • 7.3.7. France Conjunctivitis Market
      • 7.3.7.1. Market Size and Forecast, By Type
      • 7.3.7.2. Market Size and Forecast, By Disease Type
      • 7.3.7.3. Market Size and Forecast, By End User
    • 7.3.8. UK Conjunctivitis Market
      • 7.3.8.1. Market Size and Forecast, By Type
      • 7.3.8.2. Market Size and Forecast, By Disease Type
      • 7.3.8.3. Market Size and Forecast, By End User
    • 7.3.9. Italy Conjunctivitis Market
      • 7.3.9.1. Market Size and Forecast, By Type
      • 7.3.9.2. Market Size and Forecast, By Disease Type
      • 7.3.9.3. Market Size and Forecast, By End User
    • 7.3.10. Spain Conjunctivitis Market
      • 7.3.10.1. Market Size and Forecast, By Type
      • 7.3.10.2. Market Size and Forecast, By Disease Type
      • 7.3.10.3. Market Size and Forecast, By End User
    • 7.3.11. Rest of Europe Conjunctivitis Market
      • 7.3.11.1. Market Size and Forecast, By Type
      • 7.3.11.2. Market Size and Forecast, By Disease Type
      • 7.3.11.3. Market Size and Forecast, By End User
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Type
    • 7.4.3. Market Size and Forecast, By Disease Type
    • 7.4.4. Market Size and Forecast, By End User
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. Japan Conjunctivitis Market
      • 7.4.6.1. Market Size and Forecast, By Type
      • 7.4.6.2. Market Size and Forecast, By Disease Type
      • 7.4.6.3. Market Size and Forecast, By End User
    • 7.4.7. China Conjunctivitis Market
      • 7.4.7.1. Market Size and Forecast, By Type
      • 7.4.7.2. Market Size and Forecast, By Disease Type
      • 7.4.7.3. Market Size and Forecast, By End User
    • 7.4.8. India Conjunctivitis Market
      • 7.4.8.1. Market Size and Forecast, By Type
      • 7.4.8.2. Market Size and Forecast, By Disease Type
      • 7.4.8.3. Market Size and Forecast, By End User
    • 7.4.9. Australia Conjunctivitis Market
      • 7.4.9.1. Market Size and Forecast, By Type
      • 7.4.9.2. Market Size and Forecast, By Disease Type
      • 7.4.9.3. Market Size and Forecast, By End User
    • 7.4.10. South Korea Conjunctivitis Market
      • 7.4.10.1. Market Size and Forecast, By Type
      • 7.4.10.2. Market Size and Forecast, By Disease Type
      • 7.4.10.3. Market Size and Forecast, By End User
    • 7.4.11. Rest of Asia-Pacific Conjunctivitis Market
      • 7.4.11.1. Market Size and Forecast, By Type
      • 7.4.11.2. Market Size and Forecast, By Disease Type
      • 7.4.11.3. Market Size and Forecast, By End User
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Type
    • 7.5.3. Market Size and Forecast, By Disease Type
    • 7.5.4. Market Size and Forecast, By End User
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Conjunctivitis Market
      • 7.5.6.1. Market Size and Forecast, By Type
      • 7.5.6.2. Market Size and Forecast, By Disease Type
      • 7.5.6.3. Market Size and Forecast, By End User
    • 7.5.7. Saudi Arabia Conjunctivitis Market
      • 7.5.7.1. Market Size and Forecast, By Type
      • 7.5.7.2. Market Size and Forecast, By Disease Type
      • 7.5.7.3. Market Size and Forecast, By End User
    • 7.5.8. South Africa Conjunctivitis Market
      • 7.5.8.1. Market Size and Forecast, By Type
      • 7.5.8.2. Market Size and Forecast, By Disease Type
      • 7.5.8.3. Market Size and Forecast, By End User
    • 7.5.9. Rest of LAMEA Conjunctivitis Market
      • 7.5.9.1. Market Size and Forecast, By Type
      • 7.5.9.2. Market Size and Forecast, By Disease Type
      • 7.5.9.3. Market Size and Forecast, By End User

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. AFT Pharmaceuticals
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Alembic Pharmaceuticals Ltd
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. Johnson And Johnson Services Inc
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Ocular Therapeutics, Inc
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Cipla, Inc.
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Jabs Biotech Pvt. Ltd.
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Spectra Vision Care Pvt. Ltd
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Teva Pharmaceutical Industries Ltd
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. Grevis Pharmaceutical Private Limited
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Bausch Health Companies Inc
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments